Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopeniaRalph V. Boccia, James B. Bussel, Nichola Cooper et al.|British Journal of Haematology|2020Cited by 71
Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial ProgramAnne‐Marie Duliège, James B. Bussel, Donald M. Arnold et al.|Blood|2018Cited by 12
Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) PatientsRalph V. Boccia, James B. Bussel, Michael Boxer et al.|Blood|2019Cited by 3
Myeloproliferative Neoplasm Quality Of Life (MPN-QOL) Study Group: Observational Study Of Quality Of Life and Symptomatic Response In Myelofibrosis Patients Receiving Undergoing Treatment With Conventional Therapy, The Measures Trial and Allogeneic Stem Cell Transplant, The Symptoms TrialVeena Fauble, Ruben A. Mesa, Sergio Giralt et al.|Blood|2013Cited by 2